Search research articles
Contact Us
Filters
Showing results (361-370 of 408) with videos related to
Page
of 41
Sort By:
Cancer
|
November 20, 2009
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
Matthias R Benz, Johannes Czernin, Sarah M Dry, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
Matthias R Benz, Ken Herrmann, Franziska Walter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 15, 2011
Metabolic imaging allows early prediction of response to vandetanib
Martin A Walter, Matthias R Benz, Isabel J Hildebrandt, et al.
Clinical Nuclear Medicine
|
May 5, 2023
FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells
Masatoshi Hotta, Christine E Mona, Joseph G Crompton, et al.
Cancer
|
October 25, 2011
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
Matthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 18, 2009
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas
Farzin Imani, Vatche G Agopian, Martin S Auerbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 29, 2022
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
Andrei Gafita, Isabel Rauscher, Wolfgang P Fendler, et al.
Cancer Chemotherapy and Pharmacology
|
October 10, 2014
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
V Gotta, N Widmer, L A Decosterd, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 28, 2012
Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET
H Christian Rischke, Matthias R Benz, Damian Wild, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
Matthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Page
of 41
Search research articles
Search
Showing results (361-370 of 408) with videos related to
Sort By:
Page
of 41
Cancer
|
November 20, 2009
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
Matthias R Benz, Johannes Czernin, Sarah M Dry, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
Matthias R Benz, Ken Herrmann, Franziska Walter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 15, 2011
Metabolic imaging allows early prediction of response to vandetanib
Martin A Walter, Matthias R Benz, Isabel J Hildebrandt, et al.
Clinical Nuclear Medicine
|
May 5, 2023
FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells
Masatoshi Hotta, Christine E Mona, Joseph G Crompton, et al.
Cancer
|
October 25, 2011
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
Matthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 18, 2009
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas
Farzin Imani, Vatche G Agopian, Martin S Auerbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 29, 2022
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
Andrei Gafita, Isabel Rauscher, Wolfgang P Fendler, et al.
Cancer Chemotherapy and Pharmacology
|
October 10, 2014
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
V Gotta, N Widmer, L A Decosterd, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 28, 2012
Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET
H Christian Rischke, Matthias R Benz, Damian Wild, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
Matthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Page
of 41